BioCentury
ARTICLE | Clinical News

Avastin meets Phase III endpoint in cervical cancer

February 8, 2013 3:00 AM UTC

NIH's National Cancer Institute (NCI) said Genentech Inc.'s Avastin bevacizumab plus paclitaxel and either cisplatin or topotecan met the primary endpoint of improving median overall survival (OS) vs. paclitaxel and either cisplatin or topotecan alone in the Phase III GOG240 to treat cervical cancer (17 vs. 13.3 months, p-value not disclosed). The open-label, U.S. and Spanish trial enrolled 452 patients with metastatic, recurrent or persistent cervical cancer not curable with standard treatment. The unit of Roche (SIX:ROG; OTCQX:RHHBY) said it will evaluate next steps for Avastin in cervical cancer after it analyzes the data. ...